Sign In
Buy ARWR
$82.00
+0.180 (+0.220%)
At Close: Jun 22, 2026
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Monday, 15'th Dec 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 12, 2025, th
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
07:30am, Monday, 08'th Dec 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company
Fisher Asset Management LLC Has $7.14 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR
04:20am, Friday, 05'th Dec 2025
Fisher Asset Management LLC lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 6.5% in the undefined quarter, according to the company in its most recent 13F filing with the Secur
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
07:30am, Tuesday, 02'nd Dec 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy d
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of “Moderate Buy” from Analysts
02:30am, Tuesday, 02'nd Dec 2025
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the stock, MarketB
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
04:00pm, Monday, 01'st Dec 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 37th Ann
What Moved Markets This Week
07:27am, Saturday, 29'th Nov 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript
07:43pm, Thursday, 27'th Nov 2025
Arrowhead Pharmaceuticals, Inc. ( ARWR ) TD Cowen Treatment Advancements in Obesity and Related Disorders Summit November 24, 2025 1:30 PM EST Company Participants James Hamilton - Chief Medical Offic
Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today
07:16pm, Wednesday, 26'th Nov 2025
The biotech published its latest set of annual results. It's now got several revenue streams that are already significantly boosting the fundamentals.
What's Going On With Arrowhead Shares Wednesday?
03:59pm, Wednesday, 26'th Nov 2025
Arrowhead shares are trading higher Wednesday after the company reported better-than-expected fourth quarter financial results.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript
11:43pm, Tuesday, 25'th Nov 2025
Arrowhead Pharmaceuticals, Inc. ( ARWR ) Q4 2025 Earnings Call November 25, 2025 4:30 PM EST Company Participants Vincent Anzalone - Head of Investor Relations & VP Dr. Christopher Anzalone - Chairman
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
04:00pm, Tuesday, 25'th Nov 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
07:30am, Monday, 24'th Nov 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT)
Arrowhead Pharmaceuticals, Inc. ( ARWR ) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome November 18, 2025 1:30 PM EST Company Participants Vincent
Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway
11:54pm, Tuesday, 18'th Nov 2025
FDA approved Plozasiran (now REDEMPLO™) on November 18, 2025, for reducing triglycerides in adults with FCS, the first siRNA therapy for this rare disease. ARWR boasts a diversified RNAi pipeline ta
